Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Blood (2025) 146 (Supplement 1): 3885.

https://doi.org/10.1182/blood-2025-3885

Published: 2025

Journal Articles

Incidence of thrombosis and bleeding in patients receiving CAR-T cell therapy: A multicentric retrospective analysis of the Canadian experience

Luciana Melo Garcia, Tzu-Fei Wang, Michael Kennah, Abdullah Alanazi, Sarah Mckeague, John Kuruvilla, Inna Gong, Naomi Marali Xiao, Christopher Lemieux, Camille Sylvestre, Amaris Balitsky, Isabelle Fleury, Mathias Castonguay, Robert Puckrin, Hannah Cherniawsky, Amani Ahmed, Mahmoud Elsawy, Maggie McGuire, Miriam Kimpton

Blood (2025) 146 (Supplement 1): 4496.

https://doi.org/10.1182/blood-2025-4496

Published: 2025

Journal Articles

Patient journey with axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma in Canada: Manufacturing experience and impact of patient location to treatment centre

Sita Bhella, Isabelle Fleury, Christopher Lemieux, Sue ZJ Li, Lieven Billen, David Myers, Marie-Pierre Fontaine, Iwona Grzegorczyk-Manuel, Brad Du, Taryn Shuler, Natasha Kekre

Blood (2025) 146 (Supplement 1): 2730.

https://doi.org/10.1182/blood-2025-2730

Published: 2025

Journal Articles

Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large B-cell lymphoma with CD30 <1% expression

Grzegorz Nowakowski, Rebecca King, Daniel Kearney, Nancy Bartlett, Jeong-A Kim, Isabelle Fleury, Luigina Mollica, Craig Portell, Christopher Yasenchak, Keenan Fenton, Christopher Hale, Diana Hubbard, Hailing Lu, Monica Patterson, Michelle Fanale, Evelyn Rustia, Uwe Hahn

Blood (2025) 146 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2025-1905

Published: 2025

Journal Articles

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study

Wojciech Jurczak, Ana Basquiera, Isabelle Fleury, Sujun Gao, Arpad Illes, Andras Masszi, Antonio Pinto, Sanne Lugthart, Omur Sevindik, Iryna Kriachok, Elizabeth Phillips, Fei Li, Chan Cheah, Yan Xu, Mohammed Z.H. Farooqui, Jing Yang, Fangfang Lv

Blood (2025) 146 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2025-3570

Published: 2025

Journal Articles

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Blood (2024) 144 (Supplement 1): 4625.

https://doi.org/10.1182/blood-2024-205223

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

Mathias Castonguay, Jean-Sébastien Claveau, Jean Roy, Sandra Cohen, Sylvie Lachance, Imran Ahmad, Nadia M. Bambace, Lea Bernard, Jean-Sebastien Delisle, Thomas L. Kiss, Isabelle Fleury, Luigina Mollica, Denis-Claude Roy, Guy Sauvageau, Olivier Veilleux

Blood (2024) 144 (Supplement 1): 7446.

https://doi.org/10.1182/blood-2024-210718

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study

Wojciech Jurczak, Isabelle Fleury, Antonio Pinto, Sanne Lugthart, Omur Gokmen Sevindik, Iryna Kryachok, Elizabeth Phillips, Fei Li, Chan Y. Cheah, Jing Yang, Yan Xu, Siyang Leng, Fangfang Lv

Blood (2024) 144 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2024-201578

Published: 2024

Journal Articles

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2024-200836

Published: 2024

Journal Articles

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 602.

https://doi.org/10.1182/blood-2023-179474

Published: 2023

Journal Articles

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Blood (2023) 142 (Supplement 1): 1908.

https://doi.org/10.1182/blood-2023-179198

Published: 2023

Journal Articles

Prognosis of Progressive Follicular Lymphoma within 24 Months of First-Line Therapy Is Not Influenced By the Initial Regimen Intensity

Camille Gauvin, Imran Ahmad, Luigina Mollica, Sandra Cohen, Olivier Veilleux, Sylvie Lachance, Isabelle Fleury

Blood (2023) 142 (Supplement 1): 6150.

https://doi.org/10.1182/blood-2023-183021

Published: 2023

Journal Articles

Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP

Douglas A. Stewart, Lois E. Shepherd, Jill J. Dudebout, Jean-François Larouche, Neil Chua, Tara Baetz, Michael Crump, Mona Shafey, Nizar Abdel-Samad, Sue Robinson, Isabelle Fleury, Deborah Marcellus, Pamela Skrabek, Jesse Kelly, Annette E. Hay, Bingshu Chen, John Kuruvilla

Blood (2022) 140 (Supplement 1): 3734–3736.

https://doi.org/10.1182/blood-2022-163706

Published: 2022

Journal Articles

Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World

Anthea Peters, Grzegorz S. Nowakowski, Rosy Dabas, Theresa Amoloja, Zhenyi Xue, Caroline Koch, Eva E. Waltl, Isabelle Fleury

Blood (2022) 140 (Supplement 1): 3811–3813.

https://doi.org/10.1182/blood-2022-158550

Published: 2022

Journal Articles

Geographical CAR-T Unmet Needs for Patients with Large B-Cell Lymphoma in the Province of Quebec

Maria Murphy, Mathilde Fromentin, Julie Campeau, Michael Sebag, Félix Couture, Jean-François Larouche, Christopher Lemieux, Silvy Lachance, Sandra Cohen, Luigina Mollica, Olivier Veilleux, Isabelle Fleury

Blood (2022) 140 (Supplement 1): 13228–13229.

https://doi.org/10.1182/blood-2022-156473

Published: 2022

Journal Articles

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 183.

https://doi.org/10.1182/blood-2021-148302

Published: 2021

Journal Articles

Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

Blood (2020) 136 (23): 2628–2637.

https://doi.org/10.1182/blood.2020005588

Published: 2020

Includes: Supplemental data

Journal Articles

Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel

Blood (2019) 134 (Supplement_1): 2883.

https://doi.org/10.1182/blood-2019-124492

Published: 2019

Journal Articles

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Ulrich Jaeger, MD, Nina Worel, MD, Joseph P. McGuirk, DO, Peter A. Riedell, MD, Isabelle Fleury, MD, Peter Borchmann, MD, Jufen Chu, PhD, Ahmed M Abdelhady, PhD, Alessandra Forcina, MD, Lida Bubuteishvili Pacaud, MD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 5325.

https://doi.org/10.1182/blood-2019-129120

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience

Incidence of thrombosis and bleeding in patients receiving CAR-T cell therapy: A multicentric retrospective analysis of the Canadian experience

Patient journey with axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma in Canada: Manufacturing experience and impact of patient location to treatment centre

Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large B-cell lymphoma with CD30 <1% expression

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Prognosis of Progressive Follicular Lymphoma within 24 Months of First-Line Therapy Is Not Influenced By the Initial Regimen Intensity

Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World

Geographical CAR-T Unmet Needs for Patients with Large B-Cell Lymphoma in the Province of Quebec

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only